secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prime Medicine, Inc. (PRME)
CIK:        0001894562
Form:       8-K
Filed at:   2025-07-30T23:59:59+00:00
Accession:  0001628280-25-036705
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prime Medicine reports ~$101.8M cash as of June 30; terminates ATM prospectus
-----------------------------------------------------------------------------

- Preliminary cash, equivalents, and short-term investments ~$101.8M at June 30, 2025; plus $13.7M restricted cash.
- Terminated ATM prospectus under S-3 effective July 30; no further sales pending new filing.
- Sales agreement with Jefferies remains in force but ATM program currently inactive.
- Updated July 2025 corporate presentation posted on company website; includes pipeline updates.
- Company expects to report complete Q2 results in Form 10-Q; estimates subject to final adjustments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1894562/000162828025036705/0001628280-25-036705-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1894562/000162828025036705/prme-20250730.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-036705

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer